The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrestAlexandre Pichard, Jean‐Pierre Pouget, Riad Ladjohounlou et al.|Leukemia|2019Cited by 25
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitroMarion Masitsa Malenge, Jostein Dahle, Astri Fjelde Maaland et al.|PLoS ONE|2022Cited by 3